Link, Carola
Honeck, Patrick
Makabe, Akiko
Giordano, Frank Anton
Bolenz, Christian
Schaefer, Joerg
Bohrer, Markus
Lohr, Frank
Wenz, Frederik
Buergy, Daniel
Funding for this research was provided by:
BMBF (13GW0090C)
Article History
Received: 25 March 2019
Accepted: 22 May 2019
First Online: 7 June 2019
Ethics approval and consent to participate
: The study was approved by the ethics committee of Heidelberg University, Medical Faculty Mannheim (2018-509 N-MA). Written informed consent for scientific usage of clinical data was obtained from all patients.
: Consent for scientific usage of clinical data was obtained from all patients included in the study.
: CL, PH, AM, FL, JS, and MB have nothing to disclose; CB reports personal fees from medac GmbH, personal fees from Janssen, personal fees from AstraZeneca, personal fees and other from Roche AG, grants and non-financial support from Erbe Elektromedizin GmbH, outside the submitted work; FG reports grants and personal fees from NOXXON Pharma AG, grants and personal fees from CARL ZEISS MEDITEC AG, personal fees from Bristol-Myers Squibb, personal fees from Roche Pharma AG, personal fees from MSD Sharp and Dohme GmbH, personal fees from AstraZeneca GmbH, other from Implacit GmbH, non-financial support from Oncare GmbH, outside the submitted work; FW reports grants and personal fees from Elekta AB, Sweden, personal fees from Roche Pharma AG, grants, personal fees and other from Carl Zeiss Meditec AG, personal fees from Celgene GmbH, personal fees from Eli Lilly and Company, personal fees from Ipsen Pharma GmbH, outside the submitted work; DB reports personal fees from Siemens AG, personal fees from NB Capital Research GmbH, personal fees from NB Capital ApS, personal fees from b.e. Imaging GmbH outside the submitted work.